Literature DB >> 20152121

Location, location, location: contrasting roles of synaptic and extrasynaptic NMDA receptors in Huntington's disease.

Michael S Levine1, Carlos Cepeda, Véronique M André.   

Abstract

Abnormally enhanced N-methyl-D-aspartate (NMDA) receptor function is implicated in Huntington's disease (HD). In this issue of Neuron and a recent issue of Nature Medicine, an abnormal balance between the activity of NMDA receptors at synaptic (prosurvival) and extrasynaptic (proapoptotic) sites has been uncovered in a cellular and a mouse model of HD. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20152121      PMCID： PMC3119569          DOI： 10.1016/j.neuron.2010.01.010

Source DB:  PubMed          Journal:  Neuron        ISSN： 0896-6273            Impact factor:   17.173


  15 in total

1.  Regional cortical thinning in preclinical Huntington disease and its relationship to cognition.

Authors:  H D Rosas; N D Hevelone; A K Zaleta; D N Greve; D H Salat; B Fischl
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

Review 2.  N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.

Authors:  Mannie M Y Fan; Lynn A Raymond
Journal:  Prog Neurobiol       Date:  2006-12-22       Impact factor: 11.685

3.  A pilot study of the clinical efficacy and safety of memantine for Huntington's disease.

Authors:  William G Ondo; Nicte I Mejia; Christine B Hunter
Journal:  Parkinsonism Relat Disord       Date:  2006-10-13       Impact factor: 4.891

4.  An animal model for Huntington's disease.

Authors:  J T Coyle
Journal:  Biol Psychiatry       Date:  1979-04       Impact factor: 13.382

5.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

6.  Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice.

Authors:  Austen J Milnerwood; Clare M Gladding; Mahmoud A Pouladi; Alexandra M Kaufman; Rochelle M Hines; Jamie D Boyd; Rebecca W Y Ko; Oana C Vasuta; Rona K Graham; Michael R Hayden; Timothy H Murphy; Lynn A Raymond
Journal:  Neuron       Date:  2010-01-28       Impact factor: 17.173

7.  Glutamate leakage from a compartmentalized intracellular metabolic pool and activation of the lipoxygenase pathway mediate oxidative astrocyte death by reversed glutamate transport.

Authors:  Diane B Re; Imane Nafia; Christophe Melon; Keiko Shimamoto; Lydia Kerkerian-Le Goff; Laurence Had-Aissouni
Journal:  Glia       Date:  2006-07       Impact factor: 7.452

8.  Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.

Authors:  Véronique M André; Carlos Cepeda; Angela Venegas; Yeranui Gomez; Michael S Levine
Journal:  J Neurophysiol       Date:  2005-12-28       Impact factor: 2.714

9.  Mobile NMDA receptors at hippocampal synapses.

Authors:  Kenneth R Tovar; Gary L Westbrook
Journal:  Neuron       Date:  2002-04-11       Impact factor: 17.173

Review 10.  The corticostriatal pathway in Huntington's disease.

Authors:  Carlos Cepeda; Nanping Wu; Véronique M André; Damian M Cummings; Michael S Levine
Journal:  Prog Neurobiol       Date:  2006-12-13       Impact factor: 11.685
View more
  13 in total

1.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Bin Tang; Alexandre Kuhn; SoongHo Kim; Daniel H Geschwind; Timothy B Brown; Ruth Luthi-Carter; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2010-12-20       Impact factor: 6.150

Review 2.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

Review 3.  Calcium signaling and molecular mechanisms underlying neurodegenerative diseases.

Authors:  Ekaterina Pchitskaya; Elena Popugaeva; Ilya Bezprozvanny
Journal:  Cell Calcium       Date:  2017-06-30       Impact factor: 6.817

4.  Enhancement of postsynaptic GABAA and extrasynaptic NMDA receptor-mediated responses in the barrel cortex of Mecp2-null mice.

Authors:  Fu-Sun Lo; Mary E Blue; Reha S Erzurumlu
Journal:  J Neurophysiol       Date:  2015-12-16       Impact factor: 2.714

Review 5.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

Review 6.  Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.

Authors:  Carlos Cepeda; Damian M Cummings; Véronique M André; Sandra M Holley; Michael S Levine
Journal:  ASN Neuro       Date:  2010-04-07       Impact factor: 4.146

Review 7.  Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntington's and Parkinson's Disease.

Authors:  Talita Glaser; Roberta Andrejew; Ágatha Oliveira-Giacomelli; Deidiane Elisa Ribeiro; Lucas Bonfim Marques; Qing Ye; Wen-Jing Ren; Alexey Semyanov; Peter Illes; Yong Tang; Henning Ulrich
Journal:  Neurosci Bull       Date:  2020-10-07       Impact factor: 5.203

8.  Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function.

Authors:  Soong Ho Kim; Carlos A Thomas; Véronique M André; Damian M Cummings; Carlos Cepeda; Michael S Levine; Michelle E Ehrlich
Journal:  ASN Neuro       Date:  2011-06-07       Impact factor: 4.146

Review 9.  Calcium-Handling Defects and Neurodegenerative Disease.

Authors:  Sean Schrank; Nikki Barrington; Grace E Stutzmann
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-07-01       Impact factor: 9.708

Review 10.  Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases.

Authors:  Fabrizio Gardoni; Camilla Bellone
Journal:  Front Cell Neurosci       Date:  2015-03-02       Impact factor: 5.505
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.